Time's up. Here's the deal.

SmallCapFirm

(SPRC) Is A New Breakout Idea And Low Float Nasdaq Profile With 5 Must-See Potential Catalysts

June 8th

SCF Readers,

Time's up. Here's the deal.

Coming off a Tuesday profile that shot approximately 19% from an open of $.86+ to a high of $1.03, I felt compelled.

Compelled to do what you may be asking? Easy.

Compelled to step up my game and bring you an idea with even more breakout potential.

What I found was another low float Nasdaq idea.

And if it falls in line with some of my recent breakout runners:

  • 5/24's profile surged approximately 76%
  • 5/26's profile ran approximately 15%
  • 6/1's profile moved approximately 12%

... then it could be all geared up for a solid vertical move near term.

Being backed by a low float, an explosive chart history, and tons of recent, game-changing news announcements, there is only one Nasdaq profile to have on your radar today:

*SciSparc Ltd. (SPRC)*

SciSparc Ltd. is a specialty clinical-stage pharmaceutical company led by an experienced team of senior executives and scientists. SciSparc’s focus is on creating and enhancing a portfolio of technologies and assets based on cann-a-binoid pharmaceuticals.

With this focus, the Company is currently engaged in the following drug development programs based on T-H-C and/or non-psych-o-active cann-a-bidiol (C-B-D): SCI-110 for the treatment of Tourette syndrome and for the treatment of Alzheimer's disease and agitation; SCI-160 for the treatment of pain; and SCI-210 for the treatment of autism spectrum disorder and status epilepticus.

And right now, SPRC has several potential catalysts that are must-know material. They include:

No. 1 - A Tiny Float Could Allow Major Volatility

No. 2 - Initial Results Come Back Positive For Co-caine Addiction Treatment

No. 3 - A New Collaboration Could Lead To Breakthrough Pain Treatments

No. 4 - A JV With MitoCareX Bio Could Send Different Cancers And Diseases Running Scared

No. 5 - Explosive Chart History With Multiple Big Runs

But more on those in a second...

Key Details - What Makes SPRC Go

SciSparc’s proprietary compounds capitalize on the biochemistry of receptors that specialize in modulating the central nervous system to create therapeutics that mitigate the adverse symptoms associated with CNS disorders.

Their primary platforms focus on the endocann-a-binoid system. The SciSparc pipeline composes both FDA – approved, and New Chemical Entities (NCEs) which they believe have strong potential to be indicated for targeted conditions, with no existing or sufficiently effective therapies.

Enhancing existing compounds with their proprietary technologies, they have developed novel therapies that demonstrate in clinical trials heightened bioavailability, significantly improved efficacy, lower dosage requirements, better safety profiles and a reduction in side effects.

2021 - 2022 Pre-Clinical & Clinical Achievements

  • SCI–110 for Alzheimer's disease and Agitation - Recruited first patient for the Company’s Phase IIa
  • Entered an agreement with two clinical sites: Hannover Medical School in Hannover, Germany, and TelAviv Sourasky Medical Center, in Tel-Aviv, Israel, to further the Company’s Phase IIb clinical study for SCI-110 for patients suffering from Tourette Syndrome
  • Entered into agreement with The Sheba Fund for Health Services and Research, to perform a preclinical study for the evaluation of the Company's SCI-210 drug development program, for the treatment of Status Epilepticus (SE)
  • Received positive top-line results for the Company’s proprietary compound, SCI-160, in a controlled pre-clinical trial on Neuropathic and Post-operative pain
image

SPRC Market Opportunities (1)

Tourette Syndrome (TS) - $80M in 2019 and is expected to reach $98.7M by 2023.

Autism Spectrum Disorder (ASD) - The global ASD therapeutics market was approximately $3.3B in 2018 and is expected to reach approximately $4.6B by 2026.

Status Epilepticus - The global epilepsy market size would grow from $8.8B in 2018 to $9.5B towards the end of 2023.

Alzheimer’s Disease (AD) - The global Alzheimer’s therapeutics market is projected to reach $13.6B by 2027 from $7.4B in 2019.

Pain and Inflammation - The global chronic pain treatment market was valued at $77.8B in 2019.

Read more from the SPRC company presentation here.

-----

And as I mentioned above, SPRC has several potential catalysts to know right now. Check them out:

No. 1 SPRC Potential Catalyst - A Tiny Float Could Allow Major Volatility

According to the Yahoo Finance website, SPRC has a very low float like several of my recent Nasdaq breakout ideas.

In fact, the website reports SPRC to have approximately 3.09Mn shares in its float.

Why is that important? It's important on one crucial level. Volatility.

With so few shares available for trading, other potential catalysts could help to provide a spark towards a possible vertical move in the near-term.

-----

No. 2 SPRC Potential Catalyst - Initial Results Come Back Positive For Co-caine Addiction Treatment

SciSparc Ltd. Announces Initial Positive Results for the Co-caine Addiction Treatment of Clearmind Medicine Inc.

SciSparc and Clearmind recently announced the filing of a patent application related to treating cocaine addiction

TEL AVIV, Israel, June 07, 2022 (GLOBE NEWSWIRE) -- SciSparc Ltd. (NASDAQ: SPRC), a specialty clinical-stage pharmaceutical company focusing on the development of therapies to treat disorders of the central nervous system (the "Company" or "SciSparc"), today announced that initial positive pre-clinical results for treatment for co-caine addiction using MEAI, a novel psych-e-delic molecule of Clearmind Medicine Inc. (“Clearmind”) (CSE: CMND), (OTC: CMNDF), (FSE: CWY0).

Pursuant to SciSparc last announcement on June 2, 2022, whereby the Company announced the collaborated filing of a provisional patent application related to treating co-caine addiction with Clearmind based on SciSparc’s CannAmide™ compound and Clearmind’s MEAI, the pre-clinical trials show possible positive results which may positively affect our collaboration.

"We are excited about Clearmind's results, in light of the potential synergistic effect between SciSparc’s CannAmide compound and Clearmind’s MEAI, as previously demonstrated in joint studies, which reflected the dose dependency effect. We plan to continue to investigate these findings, which for the first time point to a potential treatment for co-caine addiction. Since commencing the collaboration with Clearmind, we have been able to present successful results for our proprietary combination treatment,” commented Oz Adler, SciSparc's Chief Executive Officer. "It is our intention to further investigate the effect of this treatment on different addictions and other binge behaviors."

...

Read the full article here.

-----

No. 3 SPRC Potential Catalyst - A New Collaboration Could Lead To Breakthrough Pain Treatments

SciSparc to Collaborate with Polyrizon for Brain Targeting Using Intranasal Hydrogel Systems

SciSparc will use its SCI-160 technology platform for treating pain in combination with Polyrizons' Trap and TargetTM technology

TEL AVIV, Israel, May 31, 2022 (GLOBE NEWSWIRE) -- SciSparc Ltd. (NASDAQ: SPRC), a specialty clinical-stage pharmaceutical company focusing on the development of therapies to treat disorders of the central nervous system (the "Company" or "SciSparc"), today announced it has signed a collaboration agreement with Polyrizon Ltd., a biotech company focused on the development of innovative medical device hydrogels delivered in the form of nasal sprays (“Polyrizon”).

As part of the collaboration, the two companies will work to develop a unique technology for the treatment of pain, based on SciSparc's SCI-160 platform and Polyrizon’s Trap and TargetTM intranasal drug delivery technology to target the central nervous system.

...

Dr. Adi Zuloff-Shani, SciSparc's Chief Technologies Officer, commented "SciSparc’s objective to revolutionize cann-a-binoids treatment and to develop best in class therapies continues with this collaboration agreement as we work to develop effective approaches to intranasal drug delivery, which is one of the preferred delivery options for targeting the brain. Partnering with Polyrizon and taking advantage of their innovative delivery technology may create mutual opportunities to develop treatments for pain."

...

Read the full article here.

-----

No. 4 SPRC Potential Catalyst - A JV With MitoCareX Bio Could Send Different Cancers And Diseases Running Scared

SciSparc Announces Closing of New JV Targeting Discovery of Potential Drugs for Cancers and Infectious Diseases

Research to build on studies with support from global experts in the field of small molecule drugs and gene editing

TEL AVIV, Israel, March 31, 2022 (GLOBE NEWSWIRE) -- SciSparc Ltd. (NASDAQ: SPRC) (the "Company" or "SciSparc"), a specialty, clinical-stage pharmaceutical company focusing on the development of therapies to treat disorders of the central nervous system, today announced completion of the previously announced joint venture (“JV”) agreement to focus on the discovery and development of potential drugs for cancers and other life-threatening conditions, MitoCareX Bio Ltd., an Israeli corporation (“MitoCareX Bio”) (the “JV Agreement”).

MitoCareX Bio will focus on investigating mitochondrial carriers, transport proteins crucial for cell viability. Because of mitochondrial carriers’ significant role in transporting necessary metabolites for cell functioning across the inner mitochondrial membranes, the Company believes various life-threatening conditions, such as cancers and rare mitochondrial diseases, might be treated by regulating the function of mitochondrial carriers. In humans, the mitochondrial carrier family (Solute Carrier Family 25, SLC25) consists of 53 members and is the largest solute transporter.

...

Read the full article here.

-----

No. 5 SPRC Potential Catalyst - Explosive Chart History With Multiple Big Runs

As I mentioned in a previous message, SPRC has shown the ability to make huge breakouts in the blink of an eye.

For example:

#1. On March 24th, 2022, SPRC opened at $3.95 and ran to a high of $6.99 one day later for a $3.00+ move.

#2. From a $1.95 open on May 12th, SPRC surged to a high of $3.00 and an overall intraday run of 53%.

#3. Most recently on May 24th, SPRC opened at $2.50 and ran to a high of $3.95 for an intraday blast of 58%.

Explosive quick runs.

Could SPRC have another one cooking right around the corner?

-----

SPRC Recap - Multiple Potential Catalysts To Know Now

No. 1 - A Tiny Float Could Allow Major Volatility

No. 2 - Initial Results Come Back Positive For Co-caine Addiction Treatment

No. 3 - A New Collaboration Could Lead To Breakthrough Pain Treatments

No. 4 - A JV With MitoCareX Bio Could Send Different Cancers And Diseases Running Scared

No. 5 - Explosive Chart History With Multiple Big Runs

-----

Coverage is officially initiated on SPRC. When you have time later, do this:

image

Get SPRC on your radar now.

Sincerely,

Axel Adams

Editor, SCF


Source 1


(Always Remember The St-ock Prices Could Be Significantly Lower Now From The Dates I Provided.)​

StockWireNews (stockwirenews . com) is owned by SWN Media LLC, a limited liability company (SWN Media LLC has recently retained ownership of StockNewsWire LLC). Disclosure: Make sure to always do your own research and due diligence on any day and swing trade profile I bring to your attention. I am not a license d finan.cial advise r. All potential percentage gains are based on from the low to the high of day. SmallCapFirm's full disclosure is to be read and fully understood before using SmallCapFirm's website, or joining SmallCapFirm's email or text list. By viewing SmallCapFirm's website and/or reading SmallCapFirm's email or text newsletter you are agreeing to SmallCapFirm's full disclosure which can be read at: smallcapfirm.com/disclosure StockWireNews (stockwirenews . com) is owned by SWN Media LLC, a limited liability company (SWN Media LLC has recently retained ownership of StockNewsWire LLC). An owner of SWN Media LLC owns and operates smallcapfirm . com (“SCF”), owns an interest in the limited liability company that owns and operates fierceinvestor . com (“FI”), an interest in the limited liability company that owns and operates stockstreetwire . com (SSW), and an interest in the limited liability company that owns and operates nasdaqwirenews . com (NWN) . From time to time, StockWireNews, SCF, FI, SSW, and/or NWN will publicly disseminate information about a company via website, email, SMS and other points of media. Pursuant to an agreement between SWN Media LLC and Awareness Consulting Network, LLC, SmallCapFirm (SCF) has been hired for a period beginning on 6/8/22 and ending on 6/9/22 to publicly disseminate information about (SPRC) via Website, Email and SMS. SWN Media LLC was paid nineteen thousand five hundred USD via bank wire transfer. We own zero shares of (SPRC).